Author: Manas Mishra
-
J&J expects jump in COVID vaccine sales in 2022, eyes device deals
By Manas Mishra and Carl O’Donnell (Reuters) -Johnson & Johnson on Tuesday forecast as much as $3.5 billion in sales of its COVID-19 vaccine in 2022, a 46% jump for the shot that has fared poorly compared to rivals, and said it would take a more aggressive stance on deals for its medical device unit.…





